A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label Phase 1b study to assess the safety and efficacy of
acalabrutinib when administered concomitantly with bendamustine and rituximab in subjects
with treatment naive or relapse refractory mantle cell lymphoma (Part 1), or when
administered concomitantly with venetoclax and rituximab in subjects with treatment naive
mantle cell lymphoma (Part 2).